Immunic, Inc. (IMUX)
15.40
-0.90
(-5.52%)
USD |
NASDAQ |
Aug 28, 16:00
15.40
0.00 (0.00%)
After-Hours: 20:00
Immunic Research and Development Expense (Annual) : 81.98M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 81.98M |
| December 31, 2024 | 80.05M |
| December 31, 2023 | 83.22M |
| December 31, 2022 | 71.26M |
| December 31, 2021 | 61.12M |
| December 31, 2020 | 38.64M |
| December 31, 2019 | 22.51M |
| December 31, 2018 | 9.595M |
| Date | Value |
|---|---|
| December 31, 2017 | 39.34M |
| December 31, 2016 | 30.05M |
| December 31, 2015 | 39.12M |
| December 31, 2014 | 39.48M |
| December 31, 2013 | 21.79M |
| December 31, 2012 | 5.097M |
| December 31, 2011 | 5.515M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Sionna Therapeutics, Inc. | 60.26M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |